IXHL news

Incannex Healthcare provides a corporate update, reporting patient dosing in the DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea and the grant of a U.S. composition patent expiring in 2040, supported by approximately $70 million in cash.

Incannex announced the first patient dosing in the DReAMzz Phase 2 dose-optimization study for IHL-42X, a treatment for obstructive sleep apnea expected to further support the Phase 3 development program and the company's financial outlook.

Incannex has started screening participants for its IHL-42X Phase 2 OSA trial. The company previously received FDA Fast Track designation for the drug.

Incannex Healthcare Inc. announced the USPTO has granted a patent covering its proprietary oral therapy IHL-42X for obstructive sleep apnea. This intellectual property milestone strengthens the commercial value of the asset and supports its long-term strategic development.

Incannex Healthcare received A$6.0 million in non-dilutive funding from Australia's R&D Tax Incentive Program, with an additional A$5.1 million expected later in 2026, totaling over A$11.1 million. The non-dilutive capital strengthens the company's balance sheet and provides flexibility to advance c…

Alliance Global Partners has initiated equity research coverage of Incannex Healthcare with a BUY rating and $18.00 price target, authored by analyst James Molloy. The coverage highlights the company's clinical pipeline including IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiet…